Copyright
©The Author(s) 2021.
World J Hepatol. Apr 27, 2021; 13(4): 421-432
Published online Apr 27, 2021. doi: 10.4254/wjh.v13.i4.421
Published online Apr 27, 2021. doi: 10.4254/wjh.v13.i4.421
No | Ref. | Country | Study design | Follow-up duration1 | Study population | Exclusion criteria | Duration of albumin infusion (d) | Sample size | Child-Pugh Score (A/B/C) | MELD score (albumin vs SMT)1 | Intervention | Control |
1 | Wilkinson and Sherlock[70], 1962 | England | Single centre, non-randomized | 22 mo | Cirrhosis patients with ascites despite 6 wk of dietary and diuretic therapy | HCC | 616 | 16 | NA | NA | Albumin 25-100 g until serum colloid oncotic pressure 38-40 cm of water | SMT |
2 | Gentilini et al[71], 1999 | Italy | Single centre, randomised controlled trial | 3 yr | Adult cirrhosis patients with ascites after 1 wk of bed rest and low sodium diet | Renal or cardiac failure, HCC or other malignancies, HE (grades 2-4), infections, gastrointestinal bleeding or DIVC | 1095 | 126 | 0/67/59 | NA | Albumin 12.5 g/d | SMT |
3 | Romanelli et al[72], 2006 | Italy | Single centre, randomised controlled trial | 84 mo (2-120) | Adult cirrhosis patients with ascites | Active alcohol abuse; previous ascites (grades 2 and 3) or HE; cardiac, respiratory or renal impairment; diabetes; refractory ascites; HCC or other malignancies; gastrointestinal bleeding; infections or DIVC | 1440 | 100 | 0/46/54 | NA | Albumin 25 g weekly in the first year, 25 g every two weeks thereafter | SMT |
4 | Caraceni et al[11], 2018 | Italy | Multicentre, randomised controlled trial | 18 mo | Adult cirrhosis patients with medically controlled uncomplicated ascites | Refractory ascites, recent decompensation, TIPS, HCC, liver transplantation, ongoing alcohol abuse, extrahepatic organ failure and albumin use for the treatment of ascites within one month | 540 | 431 | 64/282/85 | 12 (10–15), 13 (10–16) | Albumin 40 g twice weekly for 2 wk, and 40 g weekly up to 18 mo | SMT |
5 | Sola-Vera et al[40], 2003 | Spain | Multicentre, randomised controlled trial | 1 yr | Cirrhotic patients with ascites on the liver transplantation waiting list | Arterial hypertension; treatment with psychotropic drugs or antibiotic; TIPS; cardiac or respiratory failure; previous or currently listed for liver transplant; HIV or HCV infection, contraindications to midodrine | 365 | 196 | NIL | 16 ± 6.2, 17 ± 6.0, | Midodrine 15-30 mg/d and Albumin 40 g/15 d for 1 yr | SMT |
6 | Di Pascoli et al[13], 2019 | Italy | Non-randomised, prospective study | Mean 408 +/- 394 d | Adult cirrhosis patients with refractory ascites | HCC beyond Milan criteria or severe extrahepatic diseases | 720 | 70 | CTP 9.3 ± 1.7; 9.5 ± 1.6 | 15.2 ± 5.4, 14.9 ± 5 | Human albumin 20 grams twice per week | SMT, LVP when indicated |
7 | China et al[75], 2018 | United Kingdom | Multicentre randomised controlled trial | 6 mo | Adult cirrhosis patients hospitalised with acute decompensation and hypoalbuminemia (serum albumin < 30 g/L) | Advanced HCC; heart failure | 14 | 828 | NA | NA | Albumin 20-80 g/d until serum albumin ≥ 35 g/L | SMT |
- Citation: Wong YJ, Kumar R, Chua YJJ, Ang TL. Long-term albumin infusion in decompensated cirrhosis: A review of current literature . World J Hepatol 2021; 13(4): 421-432
- URL: https://www.wjgnet.com/1948-5182/full/v13/i4/421.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i4.421